Baseline demographics
| . | Placebo n = 19 . | PEG-rHuMGDF (μg/kg/d) . | |
|---|---|---|---|
| 2.5 (n = 19) . | 5 (n = 19) . | ||
| Age, below 60 y | 11 | 12 | 12 |
| Age, at least 60 y | 8 | 7 | 7 |
| Gender, male | 74% | 58% | 53% |
| ECOG PS 0 or 1 | 79% | 68% | 68% |
| Median platelets, × 109/L | 58 | 61 | 56 |
| Median ANC, × 109/L | 0.7 | 0.5 | 0.4 |
| Cytogenetics | |||
| Favorable | |||
| t(8;21) inv (16) | 0 | 2 (11%) | 1 (5%) |
| Unfavorable | |||
| −7, −5, del(5q), abnormalities of 3q, complex karyotypes | 3 (16%) | 3 (16%) | 3 (16%) |
| . | Placebo n = 19 . | PEG-rHuMGDF (μg/kg/d) . | |
|---|---|---|---|
| 2.5 (n = 19) . | 5 (n = 19) . | ||
| Age, below 60 y | 11 | 12 | 12 |
| Age, at least 60 y | 8 | 7 | 7 |
| Gender, male | 74% | 58% | 53% |
| ECOG PS 0 or 1 | 79% | 68% | 68% |
| Median platelets, × 109/L | 58 | 61 | 56 |
| Median ANC, × 109/L | 0.7 | 0.5 | 0.4 |
| Cytogenetics | |||
| Favorable | |||
| t(8;21) inv (16) | 0 | 2 (11%) | 1 (5%) |
| Unfavorable | |||
| −7, −5, del(5q), abnormalities of 3q, complex karyotypes | 3 (16%) | 3 (16%) | 3 (16%) |
Percentages are given based on total patient population. PS indicates performance status; ANC, absolute neutrophil count.